Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.

Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S

The Journal of clinical endocrinology and metabolism1 Mar 1996Cited by 19 (Europe PMC)

PMID8772599DOI10.1210/jcem.81.3.8772599PepBankPUB-08772599

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialSafety outcome
In previously untreated prepubertal GH-deficient children, GHRH-(1-29) therapy caused no adverse changes in general biochemical or hormonal analyses.
In plain wordsIn children with growth hormone deficiency, daily GHRH caused no harmful changes in routine blood or hormone tests.
Peptide
Sermorelin
Outcome
No significant changeGeneral biochemical and hormonal analyses
Study
n = 110
Outcome group
Adverse events · Whole body
Studied dose
30 micrograms/kg/day · subcutaneous · up to 1 yrAs given in this study (human).
Source sentences
Summary
No adverse changes in general biochemical or hormonal analyses were noted.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259905
02HumanNon-randomized trialSafety outcome
In previously untreated prepubertal GH-deficient children, GHRH-(1-29) therapy did not change fasting glucose concentration.
In plain wordsIn children with growth hormone deficiency, daily GHRH did not change fasting blood sugar.
Peptide
Sermorelin
Outcome
No significant changeFasting glucose concentration
Study
n = 110
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micrograms/kg/day · subcutaneous · up to 1 yrAs given in this study (human).
Source sentences
Summary
No change in fasting glucose concentration or excessive generation of insulin-like growth factor I occurred, and overall GHRH was well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259906
03HumanNon-randomized trialSafety outcome
In previously untreated prepubertal GH-deficient children, GHRH-(1-29) therapy did not cause excessive generation of insulin-like growth factor I.
In plain wordsIn children with growth hormone deficiency, daily GHRH did not cause excessive IGF-I levels.
Peptide
Sermorelin
Outcome
No significant changeGeneration of IGF-I
Study
n = 110
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 micrograms/kg/day · subcutaneous · up to 1 yrAs given in this study (human).
Source sentences
Summary
No change in fasting glucose concentration or excessive generation of insulin-like growth factor I occurred, and overall GHRH was well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259907
04HumanNon-randomized trialSafety outcome
In previously untreated prepubertal GH-deficient children, GHRH-(1-29) therapy was well tolerated overall.
In plain wordsIn children with growth hormone deficiency, daily GHRH was well tolerated overall.
Peptide
Sermorelin
Outcome
No significant changeOverall tolerability
Study
n = 110
Outcome group
Adverse events · Whole body
Studied dose
30 micrograms/kg/day · subcutaneous · up to 1 yrAs given in this study (human).
Source sentences
Summary
overall GHRH was well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259908
05HumanNon-randomized trialEfficacy outcome
In previously untreated prepubertal GH-deficient children, GHRH-(1-29) therapy increased mean height velocity from baseline at 6 months.
In plain wordsIn children with growth hormone deficiency, daily GHRH increased growth speed compared with before treatment after 6 months.
Peptide
Sermorelin
Outcome
IncreaseHeight velocity at 6 months
Study
n = 86
Comparator
Baseline
Outcome group
Linear growth · Endocrine and hormones
Studied dose
30 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Height velocity
4.1 cm/yr
baseline
Height velocity
8 cm/yr
6 months
Source sentences
Summary
The mean height velocity for the group increased from 4.1 +/- 0.9 cm/yr at baseline to 8.0 +/- 1.5 and 7.2 +/- 1.3 cm/yr after 6 and 12 months of therapy, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259901
06HumanNon-randomized trialEfficacy outcome
In previously untreated prepubertal GH-deficient children, GHRH-(1-29) therapy increased mean height velocity from baseline at 12 months.
In plain wordsIn children with growth hormone deficiency, daily GHRH increased growth speed compared with before treatment after 12 months.
Peptide
Sermorelin
Outcome
IncreaseHeight velocity at 12 months
Study
n = 86
Comparator
Baseline
Outcome group
Linear growth · Endocrine and hormones
Studied dose
30 micrograms/kg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Height velocity
4.1 cm/yr
baseline
Height velocity
7.2 cm/yr
12 months
Source sentences
Summary
The mean height velocity for the group increased from 4.1 +/- 0.9 cm/yr at baseline to 8.0 +/- 1.5 and 7.2 +/- 1.3 cm/yr after 6 and 12 months of therapy, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259902
07HumanNon-randomized trialEfficacy outcome
In previously untreated prepubertal GH-deficient children, the ratio of the change in bone age to height age was not significantly different from unity at 12 months.
In plain wordsIn children with growth hormone deficiency, bone age advanced in step with height age after 12 months of daily GHRH.
Peptide
Sermorelin
Outcome
No significant changeRatio of bone age change to height age change at 12 months
Study
n = 86
Outcome group
Linear growth · Endocrine and hormones
Studied dose
30 micrograms/kg/day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Ratio of change in bone age to height age
1.04 ratio
12 months
Source sentences
Summary
The ratio of the change in bone age to height age was not significantly different from unity at 12 months (1.04 +/- 0.58; P = 0.63).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259904
08HumanNon-randomized trialEfficacy outcome
In previously untreated prepubertal GH-deficient children, 74% had a good response to GHRH-(1-29) at 6 months.
In plain wordsIn children with growth hormone deficiency, about three in four had a good response to daily GHRH after 6 months.
Peptide
Sermorelin
Outcome
IncreaseGood response to GHRH at 6 months
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
30 micrograms/kg/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Children with a good response
74%
6 months
Source sentences
Summary
At 6 months, 74% of the children were considered to have a good response to GHRH.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day, sc, given at bedtime.
Report a problemFND-0877259903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.